DiscoverOn AIRR - Immune receptors in the clinicOn AIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville
On AIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville

On AIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville

Update: 2022-05-01
Share

Description

Dr. Jacob Glanville is founder and CEO of Centivax and  founder of Distributed Bio, acquired by Charles River in 2021. His work focuses on understanding and engineering  the repertoires of T and B cells to improve the response to pathogens. In this episode we discuss how to analyze receptor specificity and use this to create therapeutic antibodies and optimize vaccine response.


AIRR Community Meeting VI: “Exploring New Frontiers”: https://www.antibodysociety.org/the-airr-community/meetings/airr-community-meeting-vi-exploring-new-frontiers


iReceptor+ Seminar Series: http://www.ireceptor-plus.com/news-and-events/seminars


Comments are welcome to the inbox of onairr@airr-community.org or on social media under the hashtag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast

Comments 
loading
In Channel
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

On AIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville

On AIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville

AIRR-Community